Dunlop A. Sinclair

CIK 00017211081 companyWALTHAM, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001721108

Recent Transactions

50 trades

Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2026-01-01+14,684→ 14,684 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2026-01-01+7,961→ 161,567 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-10-10$23.72/sh−31,092→ 3,837 total
Other
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-10-10−3,837→ 0 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-09-30$22.58/sh−31,092→ 33,979 total
Other
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-09-30−3,837→ 30,142 total
Other
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-09-19−3,837→ 65,071 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-09-19$22.95/sh−31,092→ 68,908 total
Other
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-06-24−4,787→ 153,606 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-01+6,267→ 158,393 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2025-01-01+11,199→ 11,199 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-09-23$13.19/sh+4,600→ 152,126 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-09-23−4,600→ 0 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-09-16$36.09/sh−29,476→ 107,524 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-09-16$36.79/sh−7,524→ 100,000 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-06-28$13.19/sh+900→ 134,418 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-06-28−900→ 4,600 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-06-21$39.22/sh−35,305→ 138,693 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-06-21$39.63/sh−1,695→ 136,998 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-04-12$13.19/sh+1,500→ 133,518 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-04-12−1,500→ 5,500 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-03-19$57.18/sh−18,681→ 173,998 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-01+3,341→ 132,018 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-01-01$59.86/sh+5,748→ 5,748 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-12-14−6,274→ 7,000 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-12-14$13.19/sh+6,274→ 128,677 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-12-01$61.13/sh−24,000→ 192,679 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-11-17$49.99/sh−8,894→ 122,403 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-10-17$49.00/sh−24,000→ 216,679 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-04-03$74.05/sh−500→ 131,297 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-03-01$65.33/sh−500→ 131,797 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-02-01$52.61/sh−500→ 132,297 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-03$50.70/sh−500→ 132,797 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-01+3,867→ 133,297 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-01-01+7,441→ 7,441 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-12-01$49.93/sh−500→ 129,430 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-11-01$60.83/sh−500→ 129,930 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-09-08$65.00/sh−15,000→ 240,679 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2022-08-25−4,306→ 13,274 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-08-25$13.19/sh+4,306→ 130,430 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-08-16$14.00/sh+25,394→ 126,124 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2022-08-16−25,394→ 0 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-08-11$65.63/sh−30,000→ 255,679 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2022-07-21−9,606→ 25,394 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-07-21$14.00/sh+9,606→ 100,730 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-06-27$46.79/sh−1,341→ 1,341 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-06-23$45.00/sh−15,000→ 285,679 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-04-22$14.00/sh+20,000→ 91,124 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2022-04-22−20,000→ 35,000 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2022-01-01+8,554→ 8,554 total

Companies

Apellis Pharmaceuticals, Inc.
Director
$APLS

Recent Filings

Address

C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR

WALTHAM, MA, 02451

View on SEC.gov